Business

Speedboat™ Inject selected by NICE for assessment

Speedboat™ Inject selected by NICE for assessment.

articleCreo Medical Group PlcJune 1, 20235/company/creo-medical-group-plc/news/speedboattm-inject-selected-by-nice-for-assessment
Speedboat™ Inject selected by NICE for assessment

About this update from Creo Medical Group Plc

[{"type":"text","content":"\n\nCreo Medical Group plc\n(\"Creo\" the \"Company\" or the \"Group\")\n \nSpeedboat™ Inject selected by NICE for assessment\n \nCreo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that the National Institute for Health and Care Excellence (\"NICE\") has selected Speedboat Inject to be scoped and routed for guidance in respect of the endoscopic submucosal dissection (\"ESD\") of lower gastrointestinal (\"GI\") lesions. \n \nThis selection follows a committee review of headline data and initiates a multi-step process whereby Speedboat's lower GI ESD clinical and economic evidence, along with other data, is evaluated by NICE and, if appropriate, may result in a specific NICE output such as Medical Technologies Guidance.\n \nNICE selected Speedboat Inject for scoping and routing because it \"anticipate[s] the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources\".\n \nMore information on Speedboat's guidance development can be found here.\n \nCraig Gulliford, CEO of Creo Medical, said: \"We are delighted that Speedboat Inject has reached this stage with NICE and the validation this provides given the progress we are already making in the UK. We look forward to the outcome of the final stages of the review process as NICE concludes its work.\"\n \nEnquiries:\n \n\n\n\nCreo Medical Group plc\n\n\nwww.creomedical.com\n\n\n\n\nRichard Rees (CFO)\n\n\n+44 (0)1291 606 005\n\n\n\n\n\n\n\n\n\n\n\n\nCenkos Securities plc\n\n\n+44 (0)20 7397 8900\n\n\n\n\nStephen Keys / Camilla Hume (NOMAD)\n\n\n\n\n\n\n\nMichael Johnson / Russell Kerr (Sales)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNumis Securities Limited (Joint Broker)\nFreddie Barnfield / Duncan Monteith / Euan Brown\n\n\n+44 (0)20 7260 1000\n\n\n\n\n \n\n\n\n\n\n\n\nWalbrook PR Ltd\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Sam Allen /\nPhillip Marriage\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 \n\n\n\n \n \nAbout Creo Medical \n \nCreo Medical is a medical device company focused on the development and comme...

More updates from Creo Medical Group Plc